New research shows long-term survival in group of advanced melanoma patients treated with BRAF inhibitors
5 February 2016
Researchers at MIA produced 217 papers in peer-reviewed journals in 2015. Last week A/Prof Georgina Long (pictured) published another paper in the Journal of Clinical Oncology that showed long-term overall survival of patients treated with BRAF inhibitors, dabrafenib and trametinib.
Patients often respond well to these drugs initially, but about half of patients become resistant to the therapy between 12-14 months. However there are a group of patients who respond long-term on these therapies.
For the group of stage 4 patients whose melanoma had completely gone when they were initially given these drugs, most of them (62%) were still alive 3 years after starting treatment. This is a vast improvement over the survival rates only 5 years ago which were less than 10%.
Publication: GV Long, et al. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J. Clin. Oncol 2016 Jan 25.